Live Breaking News & Updates on Droia ventures

Stay updated with breaking news from Droia ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Olivier-elemento , Jason-yip , Lewis-cantley , Samuel-bakhoum , Srinath-sampath , Jonathan-carlson , Charles-hugh-jones , Bristol-myers-squibb , Microsoft-research-heath-futures , Microsoft-research , Eli-lilly-company , Volastra-therapeutics-inc

InnovationRx: Exploring The Future Of Healthcare AI

InnovationRx is your weekly digest of healthcare news. Sign up!

Boston , Massachusetts , United-states , Deerfield , Elon-musk , Eli-lilly , John-brownstein , Los-angeles , Harjinder-sandhu , Life-sciences-platforms-at-microsoft , Global-health-innovation-fund , Supreme-court

Frontier gets $80M, Galapagos' backing to make a better KRAS drug

BioPharma

Belgium , Belgian , Chris-varma , Mirati-krazati , Amgen-lumakras , Amgen , Frontier-medicines , Deerfield-management , Droia-ventures , San-francisco-based , Biotech ,

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline - Galapagos (NASDAQ:GLPG)

- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRASG12C- FMC-376 has the potential to transform patient outcomes with

Deerfield , Massachusetts , United-states , Boston , Paul-stoffel , Paul-stoffels , Chris-varma , Corporate-affairs , Frontier-medicines-corporation , Deerfield-management-company , Nasdaq , Medicines-corporation

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies

/PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the...

Shakti-narayan , Naveen-krishnan , Mark-foundation-for-cancer-research , Company-board-of-directors , Jjdc-inc , Column-group , Atlas-venture , Bristol-myers-squibb , Mirae-asset-capital-life-science , Accent-therapeutics , Mirae-asset-capital , Mirae-asset-venture-investment

Accent Therapeutics Raises $75M in Series C Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Shakti-narayan , Naveen-krishnan , Jjdc-inc , Atlas-venture , Mark-foundation-for-cancer-research , Column-group , Company-board-of-directors , Bristol-myers-squibb , Accent-therapeutics , Mirae-asset-capital-life-science , Mirae-asset-capital , Mirae-asset-venture-investment

Vico Therapeutics Raises $60M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Netherlands , Pureos-bioventures , Jeroen-vangindertael , Ackermans-van-haaren , Micah-mackison , Life-sciences , Vico-therapeutics , Droia-ventures , Kurma-partners , Polaris-partners ,

Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline

/PRNewswire/ -- Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced a $60...

Netherlands , Paribas-fortis , Jeroen-vangindertael , Piet-dejonghe , Pureos-bioventures , Micah-mackison , Ackermans-van-haaren , Berry-company-public-relations , Avh-life-sciences , Life-sciences , Droia-ventures , Kurma-partners

Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca

Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Denver , Colorado , United-states , John-monroe , George-golumbeski , Ian-clark , David-epstein , Steven-altschuler , Ramy-ibrahim , Sonoma-biotherapeutics , Jeff-kindler , Adam-kolom

Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors

Life sciences veteran’s experience leading R&D organizations and bringing more than 25 products to market will support Volastra’s growing pipeline of treatments targeting chromosomally unstable cancersNEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the...

David-nicholson , Olivier-elemento , Lewis-cantley , Samuel-bakhoum , Sandi-peterson , Volastra-therapeutics-inc , Eli-lilly-company , Schering , Allergan-pharmaceuticals , Global-head-of-research , University-of-wales , Microsoft